Trevi Therapeutics to Present at BTIG Virtual Biotechnology Conference
August 05, 2020 07:30 ET
|
Trevi Therapeutics
NEW HAVEN, Conn., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™...
Trevi Therapeutics Announces Positive Outcome of the Sample Size Re-Estimation Analysis in PRISM Trial for Severe Pruritus in Patients With Prurigo Nodularis
July 13, 2020 07:30 ET
|
Trevi Therapeutics
Independent Data Monitoring Committee Recommends Continuation of PRISM Trial with Expansion to 360 Subjects per the Adaptive Design Enrollment Expected to be Complete by Third Quarter 2021 ...
Trevi Therapeutics to Present at BMO Prescriptions for Success Healthcare Virtual Conference
June 17, 2020 16:05 ET
|
Trevi Therapeutics
NEW HAVEN, Conn., June 17, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine...
Trevi Therapeutics to Hold Virtual 2020 Annual Meeting of Stockholders
May 29, 2020 16:05 ET
|
Trevi Therapeutics
NEW HAVEN, Conn., May 29, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine...
Trevi Therapeutics Announces First Quarter 2020 Financial Results and Corporate Update
May 07, 2020 16:05 ET
|
Trevi Therapeutics
Sample Size Re-Estimation Analysis for PRISM Trial Expected in Mid-2020 New Patient Screening Re-Starting at PRISM Sites in the US and Europe Cash Position of $52.6 Million Expected to Fund...
TREVI THERAPEUTICS TO PRESENT AT NEEDHAM HEALTHCARE CONFERENCE
April 08, 2020 16:05 ET
|
Trevi Therapeutics
NEW HAVEN, Conn., April 08, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of...
TREVI THERAPEUTICS ANNOUNCES FOURTH QUARTER AND YEAR END 2019 FINANCIAL RESULTS AND CORPORATE UPDATE
March 16, 2020 08:00 ET
|
Trevi Therapeutics
Enrollment in PRISM Study Progressing - Sample Size Re-estimation Planned for mid-2020 Expect to Report Top-Line Data in both PN and IPF-Cough Trials in Second Half of 2020 Cash Position of $57.3...
Trevi Therapeutics to Present at SVB Leerink Healthcare Conference
February 20, 2020 16:05 ET
|
Trevi Therapeutics
NEW HAVEN, Conn., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine...
Trevi Therapeutics Announces Election of James V. Cassella, Ph.D. to Board of Directors
February 18, 2020 16:05 ET
|
Trevi Therapeutics
NEW HAVEN, Conn., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER...
Trevi Therapeutics Announces Third Quarter 2019 Financial Results and Recent Business Developments
November 14, 2019 16:05 ET
|
Trevi Therapeutics
Advancement of Nalbuphine ER in Clinical Development for Three Indications Cash Position of $63.5 Million Expected to Fund Operations Through At Least Q1 2021 NEW HAVEN, Conn., Nov. 14, 2019 ...